Located in Washington State’s Bothell Cascade Business Park, you will discover the headquarters of Seattle’s Genetics, Inc., a biotechnology company with a passion for treating cancer, which was established in 1998.
Within one of these buildings, you will find The Board’s President, Chief Executive Officer and Chairman, Dr. Clay Siegall.
Here you will find constant research in developing and manipulating antibodies, in which an immune response is triggered, weakening or destroying the antigens or toxins in the affected body.
This plan of action can result in Seattle Genetics becoming a major player in the pharmaceutical field.
With an estimated market value of $10 billion, along with 900 workers and the intention of adding 200 more in the future, this company rates as the biggest biotech institution in Washington State.
The primary drug for Seattle Genetics is Adcetris.
It is earmarked for treating Hodgkin’s disease, a condition in which there is an increase in the size of the lymph tissues and if the condition worsens, the liver and spleen might have issues as well.
Our rigorous research, if Adcetris prove to overcome cancer cells, this would be cutting-edge therapy and part of Oncologists first line of defense.
Of course, this would result in exponential profits in yearly sales.
This is only one of the eleven drugs Seattle Genetics have in their cancer-fighting arsenal.
Dr. Siegall is dedicated to transforming the company from biotech to a pharmaceutical enterprise.
He has also taken steps to delve into international marketing of the drugs, by opening a business in Switzerland, so Seattle Genetics can promote and distribute their own products.
Although the state of the economy and political climate might be baffling at times, Siegall remains positive about the progress of the company. He enjoys what he is doing and he does not get distracted, while advancing toward his goals.
Dr. Clay Siegall is the co-founder of Settle Genetics, Inc. With him at the helm, the company has produced a variety of cancer treatment medications, with their primary drug Adcetris getting advanced approval by the Federal Food and Drug Administration (FDA).
He received a Bachelor of Science from the University of Maryland and a Ph.D. in Genetics from Georgetown University.
Previously Siegall worked for other medical facilities including, Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute.
While remembering the words of one of his previous mentors, in which he stated, “Don’t take no for an answer”, Dr. Clay Siegall continues to persevere in the fight against cancer.